For the first time, 1536-well whole transcriptome profiling brings biologically rich readouts to primary screening and large-scale perturbation dataset generation.
In this webinar, Alithea Genomics introduces MERCURIUS™ 1536 DRUG-seq, an ultra-high-throughput transcriptomic profiling workflow designed to bring RNA-seq into 1536-well screening formats.
The session explores how discovery teams can generate large, standardized compound-response datasets across compounds, doses, cell models, and conditions, while reducing plate count, cost per profile, and batch burden compared with lower-density formats. You will learn how MERCURIUS™ 1536 DRUG-seq supports applications such as primary screening, mechanism of action discovery, toxicity profiling, compound prioritization, Cell Painting follow-up, and AI/ML-ready perturbation dataset generation.
The webinar also includes the Arctoris perspective on how automated experimental execution with the Ulysses® platform can support reproducible 1536-well transcriptomic screening, from cell preparation and compound treatment to sample preparation.
Chapters:
00:00 Introduction
02:05 Why transcriptomics needs to scale with modern screening
06:40 The limitations of lower-density transcriptomic workflows
10:25 Introducing MERCURIUS™ 1536 DRUG-seq
15:10 How the 1536-well DRUG-seq workflow works 21:00 Reducing plate count, cost per profile, and batch burden
26:20 Building AI-ready perturbation datasets
31:45 Applications in MoA discovery, toxicity profiling, and compound prioritization
37:30 Performance data and assay validation
44:10 Automation in 1536-well screening with Arctoris Ulysses®
51:35 Case studies and practical implementation considerations
57:20 Q&A and closing remarks